Turnover of BRCA1 Involves in Radiation-Induced Apoptosis by Liu, Weijun et al.
Turnover of BRCA1 Involves in Radiation-Induced
Apoptosis
Weijun Liu, Wenjun Zong, George Wu, Takeo Fujita, Wenqi Li, Judy Wu, Yong Wan*
Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United
States of America
Abstract
Background: Germ-line mutations of the breast cancer susceptibility gene-1 (BRCA1) increase the susceptibility to
tumorigenesis. The function of BRCA1 is to regulate critical cellular processes, including cell cycle progression, genomic
integrity, and apoptosis. Studies on the regulation of BRCA1 have focused intensely on transcription and phosphorylation
mechanisms. Proteolytic regulation of BRCA1 in response to stress signaling remains largely unknown. The manuscript
identified a novel mechanism by which BRCA1 is regulated by the ubiquitin-dependent degradation in response to
ionization.
Methodology/Principal Findings: Here, we report that severe ionization triggers rapid degradation of BRCA1, which in turn
results in the activation of apoptosis. Ionization-induced BRCA1 turnover is mediated via an ubiquitin-proteasomal pathway.
The stabilization of BRCA1 significantly delays the onset of ionization-induced apoptosis. We have mapped the essential
region on BRCA1, which mediates its proteolysis in response to ionization. Moreover, we have demonstrated that BRCA1
protein is most sensitive to degradation when ionization occurs during G2/M and S phase.
Conclusions/Significance: Our results suggest that ubiquitin-proteasome plays an important role in regulating BRCA1
during genotoxic stress. Proteolytic regulation of BRCA1 involves in ionization-induced apoptosis.
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Introduction
Germ-line mutations in BRCA1 gene increase the susceptibility
for the development of familial breast and ovarian cancers,
indicating that BRCA1 functions as a tumor suppressor whose
impaired activity would contribute to tumorigenesis [1]. BRCA1
has been implicated in numerous cellular processes, including
DNA repair, mRNA transcription, cell cycle regulation, chromatin
remodeling and protein ubiquitylation [2]. Since all these
processes are involved in the maintenance of genomic stability,
BRCA1 has been implicated as a key regulator of the cellular
response to DNA damage. Consistent with its involvement in
multiple cellular processes, BRCA1 has been shown to interact
with both DNA and cellular proteins, although the exact biological
function of BRCA1 remains to be defined [3,4,5,6]. So far, the
only known biochemical function of BRCA1 is its E3 ligase activity
when BRCA1 forms a heterodimer with BARD1. Both of them
have a RING-finger motif near their amino termini [7,8,9].
Importantly, tumor-associated mutation in the RING-finger
domain of BRCA1 abolishes the ubiquitin ligase activity of the
BRCA1/BARD1 complex, suggesting a strong connection
between BRCA1’s E3 ligase activity and its tumor suppressor
function [10,11].
Modulation of BRCA1 activity is important since any deficiency
in BRCA1 activity may predispose cells to enter tumorigenesis.
BRCA1 has been reported to be phosphorylated in a cell cycle
dependent manner [12,13] and also in response to ionizing
radiation [14,15]. However, the functional consequences of the
phosphorylation of BRCA1 remain unclear. Speculation exists
that BRCA1 phosphorylation may affect its cellular localiza-
tion and stability as well as altering its ability to bind other
proteins and thus, affect its biochemical activities as they are
related to DNA damage repair or gene transcription [16]. Another
way to modulate the activity of BRCA1 is through post-
translational modifications such as ubiquitylation or sumoyla-
tion. BRCA1 has been reported to be degraded through the
ubiquitin-proteasome mediated pathway [17,18]. Moreover,
the levels of protein expression for BRCA1 fluctuate during
the cell cycle and this fluctuation has been demonstrated to
be mediated in part by ubiquitin-proteasomal degradation [19].
Although the E3 ligase that targets BRCA1 for proteolysis
remains unknown, the enhanced degradation of BRCA1 by a
deregulated E3 ligase could be one of the mechanisms by which
BRCA1 levels are reduced in sporadic breast cancer [20,21]. In
addition, BRCA1 can associate with Ubc9, a mediator of the
conjugating ubiquitin-like protein SUMO1, suggesting that
BRCA1 is susceptible to sumolynation, which may either protect
the protein from degradation or affect its cellular localization
[16,22].
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tion in DNA damage response. In response to DNA damage,
many proteins that are involved in checkpoint activation (e.g.,
Cdc25A and Chk1), chromatin remodeling (e.g., H2A, H2AX),
DNA repair (e.g., FANCD2) and apoptosis regulation (e.g., Bcl-2s
and IAPs) have been reported to be poly- or mono-ubiquitylated
resulting in their degradation or activation as signal transducer
[23,24,25,26,27,28,29]. BRCA1 is thought to be one of the E3
ligases responsible for DNA damage induced-ubiquitylation based
on the co-localization of conjugated ubiquitin with BRCA1/
BARD1 [23,30]. Although BRCA1/BARD1 is able to ubiquity-
late a number of potential targets in vitro, including FANCD2,
RNA polymerase II, nucleoplasmin, p53, H2AX and histones
H2A, H2B, H3 and H4, its bone fide substrates in vivo remain
unknown [31,32,33]. To further understand the role of ubiquitin-
proteasomal system (UPS) in genomic integrity, we have
established a system to screen for degraded proteins induced by
c irradiation. Surprisingly, we found that BRCA1 is degraded in
an ubiquitin-proteasome dependent manner in response to high
dosage (20 Gy) c irradiation. Our results further suggest that
proteolytic regulation of BRCA1 is involved in c irradiation-
induced apoptosis.
Materials and Methods
Plasmids and Constructs
A set of BRCA1 mutants were engineered by PCR using the
following primers:
BRCA1(70–1863) F: 59AGGAGCCTACAAGAAAGT39
BRCA1(367–1863) F: 59GAAGATGTTCCTTGG ATA39
BRCA1(1068–1863) F: 59CAAGCAGAACTAGGTAGA39
BRCA1(1863)R: 59GTAGTGGCTGTGGGGGAT39
BRCA1(1) F: 59ATGGATTTATCTGCTCTTCGC39
BRCA1 (1–1580) R: 59AGAAGGATCAGATTCAGG39
BRCA1 (1–1477) R: 59ACTATCTGCAGACACCTC39
BRCA1 (1–1419) R: 59CTGTTCTAACACAGCTTC39
BRCA1(1–1017) R: 59TGCTTGAATGTTTTCATC39
and then were cloned into pCS2-HA, a mammalian expression
vector.
Cell culture
HeLa cells (ATCC) or mouse embryonic fibroblast BRCA1
+/+
and BRCA1
2/2 (ATCC) were cultured in Dulbecco’s modified
essential medium (Gibco-BRL) supplemented with 10% or 15%
fetal bovine serum and antibiotics. Human breast cancer cell line
MCF7 (ATCC) was grown in RPMI 1640 supplemented with
10% FBS and antibiotics. All cell lines were maintained at 37uCi n
an atmosphere of 95% air and 5% CO2.
Irradiation
Cells were irradiated using a gamma irradiator (Caesium-137
source) and allowed to recover at 37uC for varying time periods.
Proteasome inhibitor treatments
Cells were treated with proteasome inhibitor MG-132 and
ALLN at final concentrations of 20 mM and 100 mM in DMSO
(0.1%) respectively. Control cells were treated with 0.1% DMSO.
Synchronization
Cells were synchronized in S-phase with double thymidine and
in G2/M phase by thymidine-nocodazole treatment as described
previously [34]. For cell cycle progression measured by FACS
analysis, cells were fixed in 70% ethanol and stained with
propidium iodide (Sigma).
Western blotting and immunoprecipitation
Cells were pelleted, washed three times in 16PBS, and lysed
with lysis buffer (Tris 50 mM pH 7.4, NaCl 2.5 M, EDTA 5 mM,
Triton X-100 0.1%) containing 16 complete protease inhibitors
cocktail (Roche, Indianapolis, IN, USA). Total protein (30–50 mg)
was heated 5 min at 90uCi n4 6 sample buffer (Invitrogen).
Denatured samples were separated on NuPAGE 4–12% Bis-Tris
gel or 3,8% Tris-Acetate gel (Invitrogen), transferred to
nitrocellulose membrane, and probed with the indicated primary
antibody. Immunocomplexes were detected by incubation with
peroxidase-conjugated secondary antibody and ECL chemilumi-
nescence detection (Amersham). For in vivo BRCA1 ubiquitylation,
cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150
mM NaCl,1 mM PMSF, 1 mM EDTA, 1% Triton X-100, 1%
Sodium deoxycholate, 0.1% SDS, 16protease inhibitors cocktail
(Roche)) and then BRCA1 protein was immunoprecipitated from
2 mg total cell extracts for 16 hours at 4uC using anti-BRCA1
antibody. The antibody was captured by incubation using protein
A/G agarose beads (PIERCE) for 2 hour at 4uC. Beads were
washed 3 times in 1 ml ice-cold RIPA buffer followed by 2 times in
1 ml ice-cold PBS and heated for 10 minutes at 95uCi n2 6
Laemmli sample buffer. Immunoprecipitated proteins were
analyzed by Western blotting with anti-ubiquitin antibody.
RT-PCR
RNA was extracted using the TRIzol (Invitrogen) and was
reverse transcribed using random hexamers as reaction primers.
Quantitative assessments of cDNA amplification for BRCA1 [35]
and the internal reference gene 18S were performed by a
fluorescence-based real-time detection method (Biorad, Munchen,
Germany) and the SYBR Green SuperMIX (Biorad). The
oligonucleotides used are described previously (35). Poly-
merase chain reaction used consisted of 3 min at 95uC, followed
by 30 cycles at 95uC for 15 s and 60uC for 1 min. To assure
the amplicon specificity for each primer set, the PCR
products were then subjected to a melting curve analysis. For
each PCR, a standard curve was produced, using four consecutive
1:10 dilutions of a positive sample. All samples were run in
triplicate.
In vitro degradation
Cell extracts were prepared from c irradiation treated and
untreated cells as described previously [34,36].
35S-labeled HA-
tagged human wild-type BRCA1 and mutant BRCA1 proteins
were synthesized by the TNT reticulocyte lysate system (Promega).
Reaction mixtures containing 10 ng of
35S-labeled protein, 1.25
mg/ml ubiquitin (Sigma), 0.1 mg/ml cycloheximide (Sigma) and
an energy regeneration system were incubated at room temper-
ature. Aliquots were removed at indicated time points and
reactions were terminated by the addition of SDS sample buffer.
Samples were analyzed by 10% SDS-PAGE.
Colony formation assay
Long-term survival of HeLa cells was determined in a
clonogenic assay. Briefly, after treatment, cells were plated (50
cells/well) in 6 well plates. After 10 to 12 days in culture, colonies
were exposed to staining solution containing 0.25% crystal violet
and 10% formalin (35% v/v) in 80% methanol for 30 min, washed
with water, and counted.
Apoptosis analysis
After treatment, cells were harvested and washed once with
PBS. PARP cleavage, Annexin V-FITC staining and flow
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was detected by Western blotting. Annexin V-positive or sub-G1
peak cells were defined as a percentage of apoptotic cells.
Results
BRCA1 protein levels are drastically altered in response to
c irradiation
To study the role of UPS in genomic integrity, we have
established a system to screen c irradiation-induced degraded
protein [34,37]. Surprisingly, we found that BRCA1, a key protein
in DNA damage response, was degraded in response to relatively
high dose of c irradiation (20 Gy) but not in response to low dose
(5 Gy, Figure S1). To further validate this observation, HeLa cells
were treated with 20 Gy c irradiation and a time course evaluation
of BRCA1 protein expression was examined. As shown in
Figure 1A, the decrease in BRCA1 protein expression began
about 30 minutes after irradiation and undetectable BRCA1
protein levels lasted for over 12 hours, while other examined
proteins including cyclin B, ATM, PCNA and Skp2 were stable.
We also tested the stability of BRCA1 protein in response to other
genotoxic stress such as ADR (Adriamycin) and MMS (Mitomy-
cin). As shown in Figure 1B, BRCA1 was rapidly degraded in
response to c irradiation, while no detectable alteration of BRCA1
was observed in the presence of ADR or MMS. To understand the
change in stability of BRCA1 in response to the c irradiation at
different stages of the cell cycle, we examined the kinetics of
BRCA1 protein levels in MCF7 cells after exposure to c
irradiation. As shown in Figure 1C, BRCA1 was drastically
degraded in response to c irradiation in MCF7 cells, suggesting
that c irradiation-induced BRCA1 degradation is not a cell type
specific event.
Figure 1. BRCA1 protein levels are altered by c irradiation. A. BRCA1 protein levels rapidly drop in response to c irradiation in HeLa cells. Cells
were collected at different time points followed by exposure to c irradiation. BRCA1 protein levels were monitored by immunoblotting using
antibody against BRCA1. B. BRCA1 protein levels are altered by c irradiation but remain stable in response to other DNA damaging agents, including
ADR and MMS. C. c irradiation at 20 Gy induces rapid decrease of BRCA1 protein levels in human breast cancer cell MCF7.
doi:10.1371/journal.pone.0014484.g001
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To ask whether c irradiation-induced BRCA1 turnover is
mediated by the UPS, we examined the possible change in
transcriptional regulation of BRCA1 in response to severe c
irradiation. As shown in Figure 2A, no significant alteration of
BRCA1 mRNA was detected after c irradiation, while BRCA1
protein levels dropped dramatically, suggesting that the drop in
BRCA1 protein levels caused by c irradiation was due to protein
turnover. To further confirm that c irradiation-induced BRCA1
turnover is mediated by the UPS, we examined the effect of
proteasomal inhibitor on c irradiation-induced BRCA1 degrada-
tion. As shown in Figure 2A, c irradiation-induced BRCA1
degradation was largely blocked by MG132 or ALLN suggesting
c irradiation-induced BRCA1 degradation is through the protea-
somal pathway, consistent with previous reports [17,19]. To test
whether BRCA1 was conjugated to ubiquitin molecules induced by
c irradiation, we carried out immunoprecipitation of BRCA1
coupled with immunoblotting using anti-ubiquitin antibody. As
shown in Figure 2B, ubiquitin-conjugated BRCA1 was obviously
detected at 15 minutes and peaked 30 minutes after c irradiation.
Taken together, our results suggest that BRCA1 is degraded in an
ubiquitin-proteasomal dependent manner in response c irradiation.
BRCA1 protein stability is sensitive in response to c
irradiation during S and G2/M of the cell cycle
BRCA1 has been described as a multiple-functional protein, which
plays an important role in cell cycle control and apoptosis besides its
function in genomic integrity [38]. A recent study has demonstrated
that BRCA1 protein levels fluctuate during the cell cycle [19]. To test
the response of BRCA1 protein levels to cirradiation at different stages
of the cell cycle, we measured the kinetics of BRCA1 protein levels
during the cell cycle by cellular synchronization coupled with
immunoblotting. As shown in Figure 3A, BRCA1 protein accumulated
in G2/M and was maintained at relatively low levels in G1 and S
phase, which is consistent with previous observation [19]. We next
synchronized cells at different stages and then treated the synchronized
cells with c irradiation at G2/M, G1 and S phase and monitored the
kinetics of BRCA1 protein levels. Comparing the pattern of BRCA1
oscillation during the cell cycle, we noticed that exposure of the
synchronized cells to c irradiation at G2/M and S phase caused
dramatic alteration of the BRCA1 protein levels, while no significant
change was observed for the cells treated at G1 phase (Figure 3B).
Taken together, these results suggest that BRCA1 protein levels are
sensitive to c irradiation at G2/M and S phase during the cell cycle.
Mapping the domain of BRCA1 mediating the c
irradiation-induced BRCA1 degradation
To determine the region of BRCA1 that confers the degradative
response to c irradiation, we generated a series of BRCA1 deletion
mutants and examined the stability of these BRCA1 mutants using an
in vitro protein degradation assay (Figure 4A and B) [34]. In this protein
degradation assay,
35S-labeled in vitro-translated wild-type BRCA1 and
its mutants were subjected to cell extracts prepared from c irradiation-
treated cells. Aliquots were then collected at different time points.
Protein stability of the BRCA1 mutants was detected by SDS-PAGE
Figure 2. c irradiation-induced degradation of BRCA1 is mediated by the ubiquitin-proteasomal pathway. A. c irradiation-induced
degradation of BRCA1 is blocked by proteasome inhibitor MG-132 or ALLN. HeLa S3 cells were preincubated with DMSO (vehicle control), MG-132
and ALLN for 20 minutes followed by exposure to c irradiation. Cells were collected at indicated time points. BRCA1 protein levels were detected by
immunoblotting. BRCA1 mRNA was monitored using RT-PCR. B. BRCA1 is ubiquitylated prior to degradation following exposure to c irradiation. HeLa
cells were harvested at different time points after exposure to c irradiation. Cell pellet was lysed with denature-lysis buffer. Ubiquitin-conjugated
BRCA1 was pulled down by antibody against BRCA1 and further detected by immunoblotting using antibody against ubiquitin.
doi:10.1371/journal.pone.0014484.g002
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the C-terminus were quite stable in response to c irradiation, while the
wild-type and all N-terminal mutants were degraded in the extract
prepared from the cells treated with c irradiation. This result suggests
that the C-terminal region is important in facilitating the c irradiation-
induced BRCA1 degradation.
BRCA1 degradation is correlated with the cellular survival
and apoptosis after c irradiation
Our preliminary study has suggested that BRCA1 protein
stability is dependent on the dosage c irradiation. To explore the
possible physiological relevance for acute c irradiation-induced
BRCA1 degradation, we initially tested the cellular survival in
response to c irradiation using a clonogenic cell survival analysis
[39]. As shown in Figure 5A and B, c irradiation affected the cell
survival in a dosage dependent manner. Two weeks after
irradiation, cellular colonies significantly dropped at a dosage of
5 or 10 Gy, while almost no colonies were found on the plate
treated with 20 Gy, suggesting that irradiating cells with severe
doses of c irradiation induces cell death (Figure 5A and B).
To dissect the effect of c irradiation on induction of cell
apoptosis and further examine the correlation between the
Figure 3. Different sensitivities of BRCA1 protein to c irradiation at different stages of the cell cycle. A. BRCA1 protein fluctuates during
the cell cycle. HeLa cells were synchronized with double thymidine and released. Cells were collected at different time points and BRCA1 protein
levels were estimated by immunoblotting. B. BRCA1 protein levels are sensitive to c irradiation at G2/M and S phase of the cell cycle. HeLa cells were
synchronized at different stages followed by exposure to c irradiation. c irradiation-treated cells were subsequently released and collected at different
time points for detection of BRCA1 protein levels.
doi:10.1371/journal.pone.0014484.g003
Figure 4. Mapping of functional domains mediating c irradiation-induced BRCA1 degradation. A. Schematic presentation of BRCA1
functional domains, including Ring, LCXCE, NLS Rad51 binding, ATM/ATR, CDK2/cyclin A,E, TAD domains. B. Evaluation of the expression of BRCA1
mutants. C. Protein stability for BRCA1 mutants in response to c irradiation was estimated using a cell-free protein degradation assay. HeLa cell lysate
was prepared from the cells exposed to c irradiation.
35S labeled and in vitro translated BRCA1 mutant proteins were subject to the functional lysate
with supplements for protein degradation. Aliquot was collected at indicated time points and protein sample was resolved by SDS-PAGE. Protein
stability for BRCA1 mutants in the presence of c irradiation was reflected by autoradiography. Quantification was done with a Fuji PhosphorImager.
doi:10.1371/journal.pone.0014484.g004
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irradiation on cell apoptosis using three different assays, including
measuring cell cycle profile (sub-G1 peak), PARP cleavage and
Annexin-V staining [36]. As shown in Figure 5C–F, exposure of
cell to c irradiation(20 Gy) significantly induced cellular apoptosis
as demonstrated by the measurement of sub-G1 peak, PARP
cleavage as well as the results from Annexin-V staining. Given that
acute c irradiation induces rapid BRAC1 degradation, our result
suggests that the acute c irradiation induced rapid BRCA1
turnover may be correlated with cellular apoptosis after c
irradiation.
BRCA1 modulates the cellular susceptibility for apoptosis
induced by c irradiation
To analyze the biological relevance of the c irradiation
mediated decrease in BRCA1, we examined the effect of BRCA1
protein levels on cellular susceptibility for the onset of apoptosis.
We compared the susceptibility of apoptosis in mouse embryonic
fibroblast cells and their corresponding BRCA1-null cells.
Consistent with the result for HeLa cells, we observed that levels
of BRCA1 significantly decreased in response to c irradiation at 20
Gy in MEF cells (Figure 6A). Using PARP cleavage as a readout,
we estimated the onset of apoptosis between wild-type and
BRCA1-null MEF cells. As shown in Figure 6B and C, cleaved
PARP was observed in wild-type cells 9 hours after exposure to c
irradiation, while loss of BRCA1 significantly enhanced an early
PARP cleavage at 3 hours after c irradiation in BRCA1- null cells.
Our molecular mapping results showed that a loss of C-terminal
BRCT domain could stabilize BRCA1 in the presence of c
irradiation (Figure 4C). To test the effect of BRCA1 stabilization
on the c irradiation-induced apoptosis, we performed an
interference experiment by transfecting a non-degradable BRCA1
(1–1580) mutant. As shown in Figure 6D and E, overexpression of
non-degradable BRCA1 significantly delayed the initiation of
apoptosis. Similar to this observation, the overexpression of full-
length BRCA1 delayed the onset of apoptosis induced by c
irradiation as demonstrated by nuclei condensation and Annexin
V staining (Figure 6F and G). These results suggest that BRCA1
plays an important role in modulating the onset of apoptosis
induced c irradiation.
Discussion
The critical role for BRCA1 has been demonstrated in multiple
cellular processes, including cell cycle regulation, genomic
integrity, development and apoptosis [40]. In the past decade,
intense efforts have been made to address the mechanism by
which BRCA1 is regulated, especially its phosphorylation by the
checkpoint kinase and transcriptional regulation. In this study, we
report that severe c irradiation induces rapid BRCA1 degradation.
Our findings suggest that the degradation of BRCA1 by acute c
irradiation could be the one of mechanisms for initiating apoptosis.
Furthermore, our results demonstrate that UPS plays an important
role in mediating c irradiation-induced BRCA1 turnover, which in
turn facilitates apoptosis.
BRCA1 may guard the cell from genotoxic stress by
preserving the cell from apoptosis
It has been reported that BRCA1 is associated with a large
protein complex named the BRCA1-associated genome surveil-
lance complex (BASC) that includes DNA damage detection
molecules (e.g., ATM), DNA repair proteins (e.g., RAD50,
MRE11, NBS1 and BLM), and mismatch repair proteins (e.g.,
MLH1, MSH2, and MSH6) [41]. These associations allow
BRCA1 to participate in all processes required for DNA repair,
such as detection of DNA damage, prevention of abnormal DNA
replication, and replacement of damaged nucleotides. BRCA1 has
also been reported to be involved in various DNA repair pathways
including homologous recombination repair and nonhomologous
end joining after ionizing radiation [42,43] transcription-coupled
repair of oxidative-induced DNA damage [44] and global genomic
repair of UV-induced cyclobutane pyrimidine dimmers [45].
Given its important roles in DNA repair, it makes intuitive sense
that BRCA1 could enhance cell survival after DNA damage by
preventing apoptosis [46,47]. For instance, reduction of BRCA1
expression results in increased sensitivity to the DNA damaging
agents [48], whereas overexpression of BRCA1 increases resis-
tance to the DNA damaging agents [49]. Moreover, reconstitution
of BRCA1 in the BRCA1 mutant HCC1937 breast cancer line or
BRCA1-null UWB1.289 ovarian cancer cell line resulted in a
reduced sensitivity to the DNA damage chemotherapeutic agents
or ionizing radiation [50,51].
BRCA1 destruction by UPS is required for the onset of c
irradiation-induced apoptosis
Besides the physiological relevance to genotoxic stress response,
consideration must be given to situations when damaged DNA is
not able to be repaired and thus the cell undergoes apoptosis to
avoid the accumulation of mutated cells. Our findings suggest that
BRCA1 may function as a ‘‘barrier’’, mitigating the effects of
genotoxic tress by preventing the onset of apoptosis. Removal of
BRCA1 seems to permit the initiation of apoptosis induced by
acute c irradiation. In this present study, DSBs caused by 20 Gy
IR cannot be repaired as evidenced by the persistence of c-H2AX
foci in MEF cells, which eventually lead cells to undergo apoptosis.
Our data for BRCA1 analyses by loss of function or gain of
function strongly suggest that BRCA1 abundance alters the
cellular susceptibility to apoptosis. Coincidently, many well-
established anti-apoptotic proteins such as Bcl-2s(50;51),
XIAPs[52,53,54], and the inhibitor of kB( I kB) [55,56,57] have
been shown to be tightly regulated by the UPS. Degradation of
these anti-apoptotic proteins by the pro-apoptotic signaling
activated UPS results in onset of apoptosis. Finding of BRCA1
degradation in modulating onset of apoptosis suggests that BRCA1
may be an apoptotic-resisting component.
Mechanism by which BRCA1 is degraded
Protein stability of BRCA1 has been linked to the activity of
proteasome, where supplementation of proteasomal inhibitors in
the culture medium resulted in accumulation on BRCA1 [17].
Choudhury et al. demonstrated that BRCA1 protein levels
fluctuate during cell cycle and alteration of BRCA1 is mediated
by the UPS [19]. Biochemical dissection has revealed that BRCA1
can undergo ubiquitylation by a self-catalyzing mechanism via its
ring domain [8], although we must note that the putative in vivo E3
ligase involved in regulating BRCA1 during the cell cycle remains
unknown. Our data suggest the presence of an ubiquitin protein
ligase mediating the genotoxic signaling for BRCA1 degradation.
The results from mapping the degron suggest that the important
region facilitating the BRCA1 degradation lies beyond the ring
domain. The BRCT domain was thought to be important for the
degradation event. This implies that the c irradiation-induced
BRCA1 ubiquitylation/degradation is not catalyzed by its auto-
ubiquitylation, suggesting the presence of an additional E3 ligase
that mediates BRCA1 degradation induced c irradiation. The
activity of such a ubiquitin protein ligase could be mediated by one
or many different ligases involved in different stages of the cell
cycle as reflected in BRCA1 oscillation during the cell cycle. To
Turnover of BRCA1 by UPS
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14484Turnover of BRCA1 by UPS
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14484determine the potential E3 ligase involved in BRCA1 degradation,
we have taken a biased approach by immunoblotting the BRCA1
IP complex purified from the cells exposed to c irradiation with
antibodies against several known E3 ligases, including SCF, APC,
MDM2, Cul4A/DDB/ROC1 and COP1. We unfortunately have
not presently identified any putative candidate by this strategy. To
Figure 6. BRCA1 is important in modulating the onset of apoptosis in the presence of c irradiation. A. BRCA1 is degraded in response to
c irradiation in MEF cells. B. Data based on measurements of PARP cleavage showed that initiation of c irradiation-induced apoptosis (at 20 Gy) was
detected about nine hours after exposure to c irradiation. C. Loss of BRCA1 significantly enhanced the onset of apoptosis as reflected by an
approximate six hours upshift for PARP cleavage. D. Expression of a non-degradable BRCA1 in MEF cells delayed the onset of c irradiation-induced
apoptosis. E. Summary of time for activation of apoptosis under different background of BRCA1. F. Apoptosis was visualized by fluorescence
microscopy. c irradiation treated cells were fixed and stained with DAPI and nuclear morphology was observed. Arrow indicates apoptotic cells.
G. Quantification of c irradiation-induced apoptosis in MEF, MEF/BRCA1
2/2, and MEF/BRCA1
2/2 + BRCA1 cells. Cells were stained with Annexin V and
PI and apoptotic cells (Annexin V+/PI 2) were quantified by FACS. Results are mean 6 s.d. of three independent experiments (G).
doi:10.1371/journal.pone.0014484.g006
Figure 5. c irradiation induces apoptosis in HeLa S3 cells. A. Clonogenic cell survival curves of HeLa cells after exposure to c irradiation.
B. Quantification of BRCA1 protein levels in response to c irradiation at different doses. BRCA1 protein levels dropped significantly at high doses,
while it remained stable after exposure to c irradiation at low dose. Approximately 10,000 cells were plated on Petri dishes. Cells were exposed to c
irradiation and incubated in fresh medium for 10–14 days. Colonies were fixed and stained with a modified Giemsa solution (Fluka). Colonies of 50 or
more cells were counted and data were expressed as percentage of colony formation relative to untreated controls. C and D. c irradiation induces
HeLa S3 cells apoptosis in a time-dependent manner. Hela S3 cells were irradiated at 20 Gy and harvested at indicated time points. Apoptosis was
indicated as sub-G1 peak by FACS (A) and PARP cleavage by immunoblotting. E and F. Quantification of apoptosis induced by c irradiation in HeLa S3
cell using Annexin V staining. Cells were treated with c irradiation. Cells were stained with Annexin V and PI after 24 hours exposure to c irradiation.
The apoptotic cells (Annexin V+/PI 2) were subsequently quantified by FACS. Results are mean 6 s.d. of three independent experiments.
doi:10.1371/journal.pone.0014484.g005
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degradation and further elucidate the mechanism of BRCA1
proteolysis, we have initiated a strategy using BRCA1-TAP
purification by identifying BRCA1 complex in the presence of c
irradiation. This ongoing work could potentially address the
mechanism by which BRCA1 is degraded by c irradiation and
provide additional insight as to how to therapeutically modulate
BRCA1.
Supporting Information
Figure S1 Alteration of BRCA1 protein levels after exposure to
low dose of c irradiation. HeLa cells were treated with low dose c
irradiation (5 Gy). Cells were collected at different time points
followed by exposure to c irradiation. BRCA1 protein levels were
monitored by immunoblotting using antibody against BRCA1. b-
actin was measured as loading control. No obvious alteration of
BRCA1 protein levels was observed in response to low dose c
irradiation.
Found at: doi:10.1371/journal.pone.0014484.s001 (5.64 MB TIF)
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